

Docket No.: 37998-237338

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Heinz VON DER KAMMER et al.

Art Unit: 1614

Application No: 10/588,274

Examiner: Not Yet Assigned

Confirmation No: 5018

Filed: February 3, 2005

Atty. Docket No: 37998-237338

Customer No:

For: DIAGNOSTIC AND THERAPEUTIC USE OF

THE KCNE4 GENE AND PROTEIN FOR

ALZHEIMER'S DISEASE

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear on any Patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Documents BA-BE, CA and CD were cited in an International Search Report. Documents AA and CA-CD were cited in a European Search Report. Copies of the International Search Report and the European Search Report are attached.

Copies of documents BA-BE, CA and CD are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO. Copies of documents CB and CC, cited in the European Search Report only, are submitted herewith.

Application No.: 10/588,274 Docket No.: 37998-237338

If the copies were not furnished and a copy of a cited document is desired, please inform the

undersigned and a copy of the missing document will be supplied.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an

English language copy of a Search Report from a foreign patent office, issued in a counterpart application,

which refers to the relevant portion of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not

be construed to mean that a search has been made or that no other material information as defined in 37 CFR

1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall

not be construed to be an admission that any patent, publication or other information referred to therein is

"prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and

the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed

or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to

our Deposit Account No. 22-0261, under Order No. 37998-237338. A fee transmittal is also enclosed.

Dated: 4/27/2007

#848415

Respectfully submitted,

By Karta B. Lepping

Registration No.: 54,262

VENABLE LLP

P.O. Box 34385

Washington, DC 20043-9998

(202) 344-4000

(202) 344-8300 (Fax)

Attorney/Agent For Applicant

2